Clinical Study
Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention
Table 1
Patients demographic, clinical, and biochemical characterization. Results are presented in median (Q25–Q75) unless otherwise specified.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aDiabetes: fasting plasma glucose concentration ≥7.0 mmol/L or 2 h plasma glucose ≥11.1 mmol/L or confirmed as clinically known and treated diabetes mellitus; hypertension: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of antihypertensive therapy; dyslipidemia: total serum cholesterol ≥190 mg/dL or serum triglycerides ≥180 mg/dL or use of lipid-lowering medication; smoking: inhaled use of cigarettes, cigars, or pipes in any quantity, in the year previous to admission. *Significant differences to controls (). |